Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
International Biotechnology TrustLSE:IBT +0.46%36 Return-on-Tangible-Equity is 60.51% as of Feb. 2026, which is 1086% above its 10-year median of 5.10. GuruFocus rates LSE:IBT with a GF Score™ of 36/100. The stock has 4 warning signs investors should review. Among 1,199 Biotechnology companies, International Biotechnology Trust ranks better than 92.33% on this metric.
The historical rank and industry rank for International Biotechnology Trust's Return-on-Tangible-Equity or its related term are showing as below:
LSE:IBT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -7.38 Med: 5.1 Max: 27.6
Current: 27.6
During the past 13 years, International Biotechnology Trust's highest Return-on-Tangible-Equity was 27.60%. The lowest was -7.38%. And the median was 5.10%.
LSE:IBT's Return-on-Tangible-Equity is ranked better than 92.33% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs LSE:IBT: 27.60
International Biotechnology Trust (LSE:IBT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
International Biotechnology Trust Return-on-Tangible-Equity Related Terms
International Biotechnology Trust Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Biotechnology Trust Return-on-Tangible-Equity Chart
LSE:IBT vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, International Biotechnology Trust's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Biotechnology Trust Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Biotechnology Trust's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where International Biotechnology Trust's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Feb. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 60.51% mean?
International Biotechnology Trust (LSE:IBT) has a Return-on-Tangible-Equity of 60.51% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on International Biotechnology Trust and its competitors. This is 1086% above median its historical median of 5.10. According to the industry distribution chart, International Biotechnology Trust ranks #92 out of 1199 companies in the Biotechnology industry, placing it in the top 7.7%.
Is International Biotechnology Trust's Return-on-Tangible-Equity too high?
International Biotechnology Trust's current Return-on-Tangible-Equity of 60.51% is 1086% above median its 10-year median of 5.10. Based on the distribution chart, International Biotechnology Trust ranks #92 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, International Biotechnology Trust has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does International Biotechnology Trust's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, International Biotechnology Trust ranks #92 out of 1199 companies for Return-on-Tangible-Equity. This places International Biotechnology Trust in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on International Biotechnology Trust and its competitors. International Biotechnology Trust's current Return-on-Tangible-Equity is 60.51%, which is 1086% above median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Biotechnology Trust stock overvalued right now?
International Biotechnology Trust (LSE:IBT) has a current Return-on-Tangible-Equity of 60.51%. The current Return-on-Tangible-Equity is 60.51%, which is 1086% above median its 10-year median of 5.10. International Biotechnology Trust's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For International Biotechnology Trust (LSE:IBT), the current Return-on-Tangible-Equity is 60.51% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
International Biotechnology Trust Business Description
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
36GF Score
Get the complete analysis for LSE:IBT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBT has been successfully added to your 
